Core Viewpoint - UTime Ltd is addressing recent unusual share price volatility and is committed to transparency and regulatory compliance while continuing its operations normally and entering the medical industry [2][3]. Group 1: Company Operations and Developments - The company has entered the medical industry, collaborating with Dr. Ehud Baron and trial organizations, and plans to acquire a laboratory for developing a monkeypox vaccine [2]. - UTime is focused on transforming health and wellness through innovative medical wearable technologies, aiming to provide effective solutions for disease prevention and health management globally [5]. Group 2: Market Communication and Investor Relations - The company is conducting an internal investigation to determine any potential undisclosed information leaks affecting share price and may engage legal counsel for a short-selling investigation [3]. - UTime urges investors to remain rational and not be influenced by short-term market sentiment, promising to communicate any new developments through official channels [4].
Remarkable Announcement on Significant Fluctuation of the UTime's Share Price